Astatine-211: production and availability.

Published

Journal Article (Review)

The 7.2-h half life radiohalogen (211)At offers many potential advantages for targeted α-particle therapy; however, its use for this purpose is constrained by its limited availability. Astatine-211 can be produced in reasonable yield from natural bismuth targets via the (209)Bi(α,2n)(211)At nuclear reaction utilizing straightforward methods. There is some debate as to the best incident α-particle energy for maximizing 211At production while minimizing production of (210)At, which is problematic because of its 138.4-day half life α-particle emitting daughter, (210)Po. The intrinsic cost for producing (211)At is reasonably modest and comparable to that of commercially available (123)I. The major impediment to (211)At availability is attributed to the need for a medium energy α-particle beam for its production. On the other hand, there are about 30 cyclotrons in the world that have the beam characteristics required for (211)At production.

Full Text

Duke Authors

Cited Authors

  • Zalutsky, MR; Pruszynski, M

Published Date

  • July 2011

Published In

Volume / Issue

  • 4 / 3

Start / End Page

  • 177 - 185

PubMed ID

  • 22201707

Pubmed Central ID

  • 22201707

Electronic International Standard Serial Number (EISSN)

  • 1874-4729

International Standard Serial Number (ISSN)

  • 1874-4710

Digital Object Identifier (DOI)

  • 10.2174/1874471011104030177

Language

  • eng